title: Aggravation of absence seizures by carbamazepine in a genetic rat model does not induce neuronal c-Fos activation.
abstract: The mechanisms underlying carbamazepine aggravation of absence seizures are uncertain but are thought to involve enhancement of neuronal activity within the thalamocortical circuitry. We used c-Fos immunohistochemistry (cFos-ir) to examine patterns of neuronal activation and the relationship to seizure expression following administration of carbamazepine in a rat model of absence epilepsy (Genetic Absence Epilepsy Rats of Strasbourg, GAERS). Female ovariectomized GAERS implanted with extradural EEG electrodes received either 20 mg/kg carbamazepine or vehicle IP. Seizure expression was quantified by measuring the total number and duration of spike-wave discharges (SWD) and with the individual burst discharge lengths over a 90-minute EEG. This was correlated with cFos-ir in thalamocortical slices from rats killed 180 minutes after carbamazepine administration. Carbamazepine-treated rats (n = 5) had a significantly greater total duration of SWD than vehicle-treated rats (17.9% versus 8.8%, P = 0.04). Despite this aggravation of seizures, the level of cFos-ir did not differ between the treatment groups. A positive correlation was found between cFos-ir in the reticularis thalami (Rt) and the total seizure duration (R = 0.66, P = 0.04) and mean burst length (R = 0.68, P = 0.03) but not total number of seizures. The lack of difference in cFos activation patterns between carbamazepine and vehicle-treated animals suggests that the mechanism for carbamazepine aggravation of absence seizures may not involve neuronal activation but rather enhanced neuronal synchronization. The association between increased neuronal activation in the Rt and seizure burden in GAERS provides further support for the critical role of this structure in the maintenance, but not initiation, of absence seizure activity.
authors.affiliation: Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.
authors.forename: Charlott
authors.initials: C
authors.lastname: Wallengren
authors.forename: Simon
authors.initials: S
authors.lastname: Li
authors.forename: Margaret J
authors.initials: MJ
authors.lastname: Morris
authors.forename: Bianca
authors.initials: B
authors.lastname: Jupp
authors.forename: Terence J
authors.initials: TJ
authors.lastname: O'Brien
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D001921:Brain / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D002220:Carbamazepine / Q000009:adverse effects* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004569:Electroencephalography / Q000379:methods; D004832:Epilepsy, Absence / Q000209:etiology* / Q000235:genetics; D005260:Female; D007150:Immunohistochemistry / Q000379:methods; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D010052:Ovariectomy / Q000379:methods; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D051381:Rats; D011922:Rats, Mutant Strains; D013997:Time Factors
chemical_list: D000927:Anticonvulsants; D016760:Proto-Oncogene Proteins c-fos; D002220:Carbamazepine